Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00383591 | Comparison of Adjuvanted Hepatitis B Vaccine to Double Dose of Engerix™-B in Pre- /Haemodialysis Patients Aged ≥15 Years | PHASE3 | COMPLETED | 120 | — | — | Mar 1, 2002 | Jan 1, 2004 | Mar 23, 2017 | 5 | Czechia, Malaysia +1 |
| NCT00383227 | Comparison of Adjuvanted Hepatitis B Vaccine to Double Dose of Engerix™-B in Pre- /Haemodialysis Patients Aged ≥15 Years | PHASE3 | COMPLETED | 165 | — | — | Dec 1, 1999 | Nov 1, 2000 | Sep 16, 2016 | - | — |
| NCT00383383 | Comparison of Adjuvanted Hepatitis B Vaccine to Double Dose of Engerix™-B in Pre- /Haemodialysis Patients Aged ≥15 Years | PHASE3 | COMPLETED | 141 | — | — | Dec 1, 1999 | - | Oct 3, 2006 | 3 | Czechia, Malaysia +1 |
| Name | Type | Description |
|---|---|---|
| Hepatitis B adjuvanted vaccine | BIOLOGICAL | - |
| Engerix-B | BIOLOGICAL | - |
Inclusion Criteria: * Subjects were to have completed primary vaccination course. A male or female \> = 15 years of age at the time of the first vaccination. * Written informed consent obtained from the subject/ from the parents or guardians of the subject. * If the subject was a female, she was of...